Halobet0.05%

Halobetasol propionate is a super-high potency (Class I) topical corticosteroid used for the relief of the inflammatory and pruritic (itchy) manifestations of corticosteroid-responsive dermatoses, including moderate to severe plaque psoriasis and other severe inflammatory skin conditions that have not responded adequately to less potent topical steroids.

Contains Halobet 0.05% 0.05% as the active ingredient, available as a topical cream, ointment, lotion, or foam.

Halobetasol propionate is one of the most potent topical corticosteroids available, classified as super-high potency (Class I), reserved for severe, stubborn inflammatory skin conditions such as plaque psoriasis that have not responded to milder steroids. Because of its strength, treatment is strictly limited to no more than 2 consecutive weeks and no more than 50 grams per week, given a real risk of suppressing the body's own adrenal hormone production (HPA axis suppression) with more prolonged or excessive use. It is not intended for ordinary eczema or minor skin irritation, where a much milder steroid would be appropriate and safer.

Therapeutic Class: Topical Corticosteroid (Super-High Potency, Class I)

The extent of percutaneous absorption of topical corticosteroids like halobetasol depends on the vehicle used, the integrity of the skin barrier, and whether an occlusive dressing is used; even brief occlusion can markedly enhance penetration and systemic absorption. Because halobetasol is formulated at super-high potency specifically to maximize local anti-inflammatory effect, systemic absorption sufficient to affect the hypothalamic-pituitary-adrenal (HPA) axis can occur even with topical use if the 2-week/50 g weekly limit is exceeded.

• For dermatological use only - not for ophthalmic (eye) use
• Apply a thin layer to the affected area and rub in gently and completely; do not apply more than directed
• Wash hands after application, unless the hands are the area being treated
• Do not use with occlusive dressings or bandages unless specifically directed by a doctor, given significantly increased absorption risk
• Discontinue once the condition is controlled, rather than continuing for the full potential 2-week period if improvement occurs sooner

No clinically significant systemic drug interactions are well established for topical halobetasol at recommended doses and durations. Avoid applying other topical products to the same treated area without checking with a pharmacist or doctor, since layering products may alter absorption.

Common side effects

• Burning, stinging, or itching at the application site
• Skin irritation or dryness

Serious side effects (require prompt medical attention)

• Hypothalamic-pituitary-adrenal (HPA) axis suppression: can occur with use beyond the recommended duration or amount, potentially leading to glucocorticosteroid insufficiency, including Cushing's syndrome, hyperglycemia (raised blood sugar), and glucosuria (glucose in the urine); adhere strictly to the 2-week/50 g weekly limit to minimize this risk.
• Skin thinning (atrophy), stretch marks (striae), visible blood vessels, and increased bruising with prolonged or excessive use.
• Signs of a severe allergic reaction: rash, swelling, difficulty breathing.
• Signs of skin infection, which may be masked by the anti-inflammatory effect of the steroid.

Pregnancy

Systemic absorption of super-high-potency topical corticosteroids can occur, particularly with use beyond the recommended duration or amount; use during pregnancy should only occur if a doctor determines it is necessary, at the lowest effective dose and shortest duration.

Breastfeeding

It is not known whether topical halobetasol results in detectable systemic levels in breast milk; caution is advised, and application to the breast area before nursing should be avoided.

• Strict duration and dose limits are essential: do not use for longer than 2 consecutive weeks, and do not exceed 50 g per week, given the real risk of HPA axis suppression with this super-high potency steroid.
• Not for use in children under 12 without specific medical guidance, given increased systemic absorption risk relative to body size in this population.
• Discontinue treatment once control of the skin condition is achieved, rather than continuing for the full potential duration.
• If no improvement occurs within 2 weeks, the original diagnosis should be reassessed, since this may indicate the condition is not actually corticosteroid-responsive, or requires a different treatment approach.
• Avoid use on the face, groin, axillae, or under occlusive dressings, given increased absorption in these areas/conditions.

Excessive or prolonged use beyond the recommended duration and amount significantly increases the risk of HPA axis suppression and its associated complications (Cushing's syndrome, raised blood glucose, glucose in the urine), as well as local skin thinning and related changes. If accidentally ingested, contact a doctor or pharmacist for advice, particularly for a child. Discontinue use and consult a doctor if unexpected systemic symptoms develop.

Store at controlled room temperature (generally 20-25°C, with excursions permitted between 15-30°C), away from excessive heat, with the container tightly closed after use.

• Children under 12 years: Use is not recommended, given increased systemic absorption and adrenal suppression risk relative to body surface area in this population.
• Elderly: May have thinner skin more prone to steroid-related atrophy; use with appropriate caution and adherence to duration/dose limits.
• Patients with diabetes: Monitor blood glucose more closely if using this medicine, given the risk of steroid-induced hyperglycemia with excessive or prolonged use.

Treatment is strictly limited to a maximum of 2 consecutive weeks, with a total weekly amount not exceeding 50 g, given halobetasol's super-high potency and associated HPA axis suppression risk. Therapy should be discontinued as soon as the skin condition is controlled, and reassessed by a doctor if no improvement is seen within 2 weeks.

Drug Class: Super-high potency (Class I) topical glucocorticoid

Halobetasol works by binding to glucocorticoid receptors in skin cells, inducing production of proteins (lipocortins) that suppress the release of arachidonic acid, the precursor of inflammatory mediators such as prostaglandins and leukotrienes. This produces a strong anti-inflammatory, antipruritic, and vasoconstrictive effect, rapidly reducing the redness, scaling, and itching characteristic of severe corticosteroid-responsive dermatoses like plaque psoriasis.

Use of Halobet 0.05% in children under 12 years of age is not recommended, given increased systemic absorption relative to body surface area and the associated risk of HPA axis suppression in this population; if considered necessary for a severe condition, use should occur only under specialist medical guidance with close monitoring.